Article
Acute myeloid leukaemia (AML) harbouring KMT2A-PTD: should it be considered as a myelodysplasia-related abnormality?
Journal of clinical pathology - 17 Apr 2026
Kannan Narasimhapriyan, Achrekar Aarti, Terse Vishram, Gawde Vaibhav, Joshi Swapnali, Bhanshe Prasanna, Chaudhary Shruti, Salunke Pratiksha, Ghogale Sitaram, Deshpande Nilesh, Shetty Dhanlaxmi, Shetty Alok, Mirgh Sumeet, Nayak Lingaraj, Gokarn Anant, Punatar Sachin, Jain Hasmukh, Bagal Bhausaheb, Sengar Manju, Khattry Navin, Rajpal Sweta, Chatterjee Gaurav, Tembhare Prashant, Subramanian Papagudi G, Patkar Nikhil
Abstract excerpt
AIMS: Although acute myeloid leukaemia (AML), myelodysplasia-related (AML-MR), can be defined solely by molecular abnormalities, legacy studies did not analyse the KMT2A gene. The KMT2A-partial tandem duplication (KMT2A-PTD) is described in myelodysplastic neoplasms (MDS) as well as AML. We describe the clinical, morphological, immunophenotypic and molecular features of AML harbouring KMT2A-PTD. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
